Dynavax Technologies | Beneficio Operativo



Operating Profit Cambio Fecha
AbbVie USD -1490000000 5.32B 2024-12
Adma Biologics USD 37.08M 2.56M 2024-12
Amgen USD 2.31B 182M 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Dynavax Technologies USD -1632000 11.71M 2024-12
Gilead Sciences USD 2.45B 1.56B 2024-12
Glaxosmithkline GBP 702M 513M 2024-12
Merck USD 4.3B 369M 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Pfizer USD -409000000 5.57B 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Roche Holding CHF 4.39B 1.04B 2024-12
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
TG Therapeutics USD 29.95M 17.52M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Dynavax Technologies Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.